nodes	percent_of_prediction	percent_of_DWPC	metapath
Methsuximide—Ataxia—Altretamine—ovarian cancer	0.0326	0.0464	CcSEcCtD
Methsuximide—Pancytopenia—Altretamine—ovarian cancer	0.0285	0.0405	CcSEcCtD
Methsuximide—CACNA1G—decidua—ovarian cancer	0.0231	0.153	CbGeAlD
Methsuximide—CACNA1I—testis—ovarian cancer	0.0214	0.141	CbGeAlD
Methsuximide—CACNA1H—myometrium—ovarian cancer	0.0204	0.135	CbGeAlD
Methsuximide—Leukopenia—Altretamine—ovarian cancer	0.0187	0.0266	CcSEcCtD
Methsuximide—Anorexia—Altretamine—ovarian cancer	0.0163	0.0231	CcSEcCtD
Methsuximide—CACNA1I—lymph node—ovarian cancer	0.0155	0.102	CbGeAlD
Methsuximide—Decreased appetite—Altretamine—ovarian cancer	0.0148	0.0211	CcSEcCtD
Methsuximide—CACNA1H—gonad—ovarian cancer	0.0133	0.088	CbGeAlD
Methsuximide—CACNA1H—uterus—ovarian cancer	0.0132	0.0874	CbGeAlD
Methsuximide—CACNA1H—female reproductive system—ovarian cancer	0.0119	0.0786	CbGeAlD
Methsuximide—Ataxia—Chlorambucil—ovarian cancer	0.0116	0.0165	CcSEcCtD
Methsuximide—Dizziness—Altretamine—ovarian cancer	0.0113	0.016	CcSEcCtD
Methsuximide—Vomiting—Altretamine—ovarian cancer	0.0108	0.0154	CcSEcCtD
Methsuximide—CACNA1H—female gonad—ovarian cancer	0.0108	0.0715	CbGeAlD
Methsuximide—Nausea—Altretamine—ovarian cancer	0.0101	0.0144	CcSEcCtD
Methsuximide—Pancytopenia—Chlorambucil—ovarian cancer	0.0101	0.0144	CcSEcCtD
Methsuximide—CACNA1H—testis—ovarian cancer	0.00958	0.0634	CbGeAlD
Methsuximide—Stevens-Johnson syndrome—Chlorambucil—ovarian cancer	0.00942	0.0134	CcSEcCtD
Methsuximide—Pancytopenia—Topotecan—ovarian cancer	0.00901	0.0128	CcSEcCtD
Methsuximide—Pancytopenia—Melphalan—ovarian cancer	0.00883	0.0125	CcSEcCtD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—BCL9—ovarian cancer	0.00878	0.0653	CbGpPWpGaD
Methsuximide—Erythema multiforme—Chlorambucil—ovarian cancer	0.00807	0.0115	CcSEcCtD
Methsuximide—Pancytopenia—Vinorelbine—ovarian cancer	0.00771	0.011	CcSEcCtD
Methsuximide—Weight decreased—Vinorelbine—ovarian cancer	0.00735	0.0104	CcSEcCtD
Methsuximide—CACNA1H—lymph node—ovarian cancer	0.00694	0.046	CbGeAlD
Methsuximide—Leukopenia—Chlorambucil—ovarian cancer	0.00665	0.00945	CcSEcCtD
Methsuximide—Confusional state—Chlorambucil—ovarian cancer	0.00611	0.00868	CcSEcCtD
Methsuximide—Ataxia—Paclitaxel—ovarian cancer	0.00594	0.00844	CcSEcCtD
Methsuximide—Leukopenia—Topotecan—ovarian cancer	0.00592	0.00841	CcSEcCtD
Methsuximide—Leukopenia—Melphalan—ovarian cancer	0.0058	0.00823	CcSEcCtD
Methsuximide—Anorexia—Chlorambucil—ovarian cancer	0.00578	0.00821	CcSEcCtD
Methsuximide—Decreased appetite—Chlorambucil—ovarian cancer	0.00527	0.00749	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Chlorambucil—ovarian cancer	0.00523	0.00744	CcSEcCtD
Methsuximide—Pancytopenia—Paclitaxel—ovarian cancer	0.00519	0.00737	CcSEcCtD
Methsuximide—Anorexia—Topotecan—ovarian cancer	0.00514	0.00731	CcSEcCtD
Methsuximide—CYP2C19—vagina—ovarian cancer	0.00511	0.0338	CbGeAlD
Methsuximide—Leukopenia—Vinorelbine—ovarian cancer	0.00506	0.00719	CcSEcCtD
Methsuximide—Anorexia—Melphalan—ovarian cancer	0.00504	0.00716	CcSEcCtD
Methsuximide—Ataxia—Docetaxel—ovarian cancer	0.00504	0.00715	CcSEcCtD
Methsuximide—Feeling abnormal—Chlorambucil—ovarian cancer	0.005	0.0071	CcSEcCtD
Methsuximide—Hiccups—Epirubicin—ovarian cancer	0.00498	0.00707	CcSEcCtD
Methsuximide—Gastrointestinal pain—Chlorambucil—ovarian cancer	0.00496	0.00704	CcSEcCtD
Methsuximide—Weight decreased—Paclitaxel—ovarian cancer	0.00494	0.00702	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Paclitaxel—ovarian cancer	0.00483	0.00686	CcSEcCtD
Methsuximide—Urticaria—Chlorambucil—ovarian cancer	0.00482	0.00684	CcSEcCtD
Methsuximide—Abdominal pain—Chlorambucil—ovarian cancer	0.00479	0.00681	CcSEcCtD
Methsuximide—Decreased appetite—Topotecan—ovarian cancer	0.00469	0.00666	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Topotecan—ovarian cancer	0.00466	0.00662	CcSEcCtD
Methsuximide—Haematuria—Paclitaxel—ovarian cancer	0.00464	0.0066	CcSEcCtD
Methsuximide—Constipation—Topotecan—ovarian cancer	0.00462	0.00656	CcSEcCtD
Methsuximide—Hiccups—Doxorubicin—ovarian cancer	0.0046	0.00654	CcSEcCtD
Methsuximide—Decreased appetite—Melphalan—ovarian cancer	0.00459	0.00653	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Melphalan—ovarian cancer	0.00456	0.00648	CcSEcCtD
Methsuximide—Feeling abnormal—Topotecan—ovarian cancer	0.00445	0.00632	CcSEcCtD
Methsuximide—Phenobarbital—CYP1B1—ovarian cancer	0.00444	0.42	CrCbGaD
Methsuximide—Gastrointestinal pain—Topotecan—ovarian cancer	0.00441	0.00627	CcSEcCtD
Methsuximide—Anorexia—Vinorelbine—ovarian cancer	0.0044	0.00625	CcSEcCtD
Methsuximide—Pancytopenia—Docetaxel—ovarian cancer	0.0044	0.00624	CcSEcCtD
Methsuximide—Urticaria—Topotecan—ovarian cancer	0.00429	0.00609	CcSEcCtD
Methsuximide—Abdominal pain—Topotecan—ovarian cancer	0.00427	0.00606	CcSEcCtD
Methsuximide—Urticaria—Melphalan—ovarian cancer	0.0042	0.00596	CcSEcCtD
Methsuximide—Weight decreased—Docetaxel—ovarian cancer	0.00419	0.00595	CcSEcCtD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—SMARCA4—ovarian cancer	0.00418	0.0311	CbGpPWpGaD
Methsuximide—Diarrhoea—Chlorambucil—ovarian cancer	0.00415	0.00589	CcSEcCtD
Methsuximide—Erythema multiforme—Paclitaxel—ovarian cancer	0.00413	0.00587	CcSEcCtD
Methsuximide—CYP2C19—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1B1—ovarian cancer	0.00411	0.0306	CbGpPWpGaD
Methsuximide—Stevens-Johnson syndrome—Docetaxel—ovarian cancer	0.00409	0.00581	CcSEcCtD
Methsuximide—Decreased appetite—Vinorelbine—ovarian cancer	0.00401	0.0057	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.00399	0.00566	CcSEcCtD
Methsuximide—Constipation—Vinorelbine—ovarian cancer	0.00395	0.00561	CcSEcCtD
Methsuximide—Vomiting—Chlorambucil—ovarian cancer	0.00385	0.00548	CcSEcCtD
Methsuximide—Feeling abnormal—Vinorelbine—ovarian cancer	0.0038	0.0054	CcSEcCtD
Methsuximide—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.00378	0.00536	CcSEcCtD
Methsuximide—CYP2C19—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1B1—ovarian cancer	0.00374	0.0278	CbGpPWpGaD
Methsuximide—Tension—Paclitaxel—ovarian cancer	0.00373	0.0053	CcSEcCtD
Methsuximide—Nervousness—Paclitaxel—ovarian cancer	0.0037	0.00525	CcSEcCtD
Methsuximide—Diarrhoea—Topotecan—ovarian cancer	0.00369	0.00525	CcSEcCtD
Methsuximide—Urticaria—Vinorelbine—ovarian cancer	0.00367	0.00521	CcSEcCtD
Methsuximide—Abdominal pain—Vinorelbine—ovarian cancer	0.00365	0.00518	CcSEcCtD
Methsuximide—Diarrhoea—Melphalan—ovarian cancer	0.00362	0.00514	CcSEcCtD
Methsuximide—Nausea—Chlorambucil—ovarian cancer	0.0036	0.00512	CcSEcCtD
Methsuximide—Vision blurred—Paclitaxel—ovarian cancer	0.00359	0.00509	CcSEcCtD
Methsuximide—Dizziness—Topotecan—ovarian cancer	0.00357	0.00507	CcSEcCtD
Methsuximide—Erythema multiforme—Docetaxel—ovarian cancer	0.0035	0.00498	CcSEcCtD
Methsuximide—Vomiting—Topotecan—ovarian cancer	0.00343	0.00487	CcSEcCtD
Methsuximide—Leukopenia—Paclitaxel—ovarian cancer	0.00341	0.00484	CcSEcCtD
Methsuximide—Rash—Topotecan—ovarian cancer	0.0034	0.00483	CcSEcCtD
Methsuximide—Dermatitis—Topotecan—ovarian cancer	0.0034	0.00483	CcSEcCtD
Methsuximide—Ataxia—Epirubicin—ovarian cancer	0.0034	0.00483	CcSEcCtD
Methsuximide—Headache—Topotecan—ovarian cancer	0.00338	0.0048	CcSEcCtD
Methsuximide—Vomiting—Melphalan—ovarian cancer	0.00336	0.00477	CcSEcCtD
Methsuximide—Rash—Melphalan—ovarian cancer	0.00333	0.00473	CcSEcCtD
Methsuximide—Dermatitis—Melphalan—ovarian cancer	0.00333	0.00473	CcSEcCtD
Methsuximide—Nausea—Topotecan—ovarian cancer	0.00321	0.00455	CcSEcCtD
Methsuximide—Diarrhoea—Vinorelbine—ovarian cancer	0.00316	0.00449	CcSEcCtD
Methsuximide—Ataxia—Doxorubicin—ovarian cancer	0.00314	0.00446	CcSEcCtD
Methsuximide—Nausea—Melphalan—ovarian cancer	0.00314	0.00446	CcSEcCtD
Methsuximide—Confusional state—Paclitaxel—ovarian cancer	0.00313	0.00445	CcSEcCtD
Methsuximide—CACNA1I—NCAM signaling for neurite out-growth—IL6ST—ovarian cancer	0.0031	0.0231	CbGpPWpGaD
Methsuximide—Eosinophilia—Epirubicin—ovarian cancer	0.00309	0.00439	CcSEcCtD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—PARP1—ovarian cancer	0.00308	0.0229	CbGpPWpGaD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—CCND2—ovarian cancer	0.00305	0.0227	CbGpPWpGaD
Methsuximide—Dizziness—Vinorelbine—ovarian cancer	0.00305	0.00434	CcSEcCtD
Methsuximide—Pancytopenia—Epirubicin—ovarian cancer	0.00296	0.00421	CcSEcCtD
Methsuximide—Anorexia—Paclitaxel—ovarian cancer	0.00296	0.00421	CcSEcCtD
Methsuximide—Vomiting—Vinorelbine—ovarian cancer	0.00294	0.00417	CcSEcCtD
Methsuximide—Rash—Vinorelbine—ovarian cancer	0.00291	0.00414	CcSEcCtD
Methsuximide—Dermatitis—Vinorelbine—ovarian cancer	0.00291	0.00413	CcSEcCtD
Methsuximide—Headache—Vinorelbine—ovarian cancer	0.00289	0.00411	CcSEcCtD
Methsuximide—Leukopenia—Docetaxel—ovarian cancer	0.00289	0.0041	CcSEcCtD
Methsuximide—Eosinophilia—Doxorubicin—ovarian cancer	0.00286	0.00406	CcSEcCtD
Methsuximide—Weight decreased—Epirubicin—ovarian cancer	0.00282	0.00401	CcSEcCtD
Methsuximide—Insomnia—Paclitaxel—ovarian cancer	0.00281	0.00399	CcSEcCtD
Methsuximide—Drowsiness—Epirubicin—ovarian cancer	0.00278	0.00395	CcSEcCtD
Methsuximide—Somnolence—Paclitaxel—ovarian cancer	0.00276	0.00392	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Epirubicin—ovarian cancer	0.00276	0.00392	CcSEcCtD
Methsuximide—Pancytopenia—Doxorubicin—ovarian cancer	0.00274	0.0039	CcSEcCtD
Methsuximide—Nausea—Vinorelbine—ovarian cancer	0.00274	0.0039	CcSEcCtD
Methsuximide—Decreased appetite—Paclitaxel—ovarian cancer	0.0027	0.00383	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.00268	0.00381	CcSEcCtD
Methsuximide—Constipation—Paclitaxel—ovarian cancer	0.00266	0.00377	CcSEcCtD
Methsuximide—Haematuria—Epirubicin—ovarian cancer	0.00265	0.00377	CcSEcCtD
Methsuximide—Confusional state—Docetaxel—ovarian cancer	0.00265	0.00377	CcSEcCtD
Methsuximide—Weight decreased—Doxorubicin—ovarian cancer	0.00261	0.00371	CcSEcCtD
Methsuximide—Drowsiness—Doxorubicin—ovarian cancer	0.00258	0.00366	CcSEcCtD
Methsuximide—Feeling abnormal—Paclitaxel—ovarian cancer	0.00256	0.00364	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	0.00255	0.00363	CcSEcCtD
Methsuximide—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.00254	0.00361	CcSEcCtD
Methsuximide—Anorexia—Docetaxel—ovarian cancer	0.00251	0.00356	CcSEcCtD
Methsuximide—Urticaria—Paclitaxel—ovarian cancer	0.00247	0.0035	CcSEcCtD
Methsuximide—Haematuria—Doxorubicin—ovarian cancer	0.00246	0.00349	CcSEcCtD
Methsuximide—Abdominal pain—Paclitaxel—ovarian cancer	0.00245	0.00349	CcSEcCtD
Methsuximide—CACNA1I—Developmental Biology—NR5A1—ovarian cancer	0.00243	0.018	CbGpPWpGaD
Methsuximide—Insomnia—Docetaxel—ovarian cancer	0.00238	0.00338	CcSEcCtD
Methsuximide—Erythema multiforme—Epirubicin—ovarian cancer	0.00236	0.00336	CcSEcCtD
Methsuximide—Somnolence—Docetaxel—ovarian cancer	0.00234	0.00332	CcSEcCtD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—TERT—ovarian cancer	0.00229	0.017	CbGpPWpGaD
Methsuximide—Decreased appetite—Docetaxel—ovarian cancer	0.00229	0.00325	CcSEcCtD
Methsuximide—CACNA1G—NCAM signaling for neurite out-growth—IL6ST—ovarian cancer	0.00229	0.017	CbGpPWpGaD
Methsuximide—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.00227	0.00323	CcSEcCtD
Methsuximide—Constipation—Docetaxel—ovarian cancer	0.00225	0.0032	CcSEcCtD
Methsuximide—CACNA1H—NCAM signaling for neurite out-growth—IL6ST—ovarian cancer	0.00221	0.0165	CbGpPWpGaD
Methsuximide—Erythema multiforme—Doxorubicin—ovarian cancer	0.00219	0.00311	CcSEcCtD
Methsuximide—Feeling abnormal—Docetaxel—ovarian cancer	0.00217	0.00308	CcSEcCtD
Methsuximide—Gastrointestinal pain—Docetaxel—ovarian cancer	0.00215	0.00306	CcSEcCtD
Methsuximide—Tension—Epirubicin—ovarian cancer	0.00213	0.00303	CcSEcCtD
Methsuximide—Diarrhoea—Paclitaxel—ovarian cancer	0.00212	0.00302	CcSEcCtD
Methsuximide—Nervousness—Epirubicin—ovarian cancer	0.00211	0.003	CcSEcCtD
Methsuximide—Abdominal pain—Docetaxel—ovarian cancer	0.00208	0.00296	CcSEcCtD
Methsuximide—Ketazolam—ABCB1—ovarian cancer	0.00206	0.195	CrCbGaD
Methsuximide—Dizziness—Paclitaxel—ovarian cancer	0.00205	0.00292	CcSEcCtD
Methsuximide—Vision blurred—Epirubicin—ovarian cancer	0.00205	0.00291	CcSEcCtD
Methsuximide—Tension—Doxorubicin—ovarian cancer	0.00198	0.00281	CcSEcCtD
Methsuximide—Vomiting—Paclitaxel—ovarian cancer	0.00197	0.0028	CcSEcCtD
Methsuximide—Rash—Paclitaxel—ovarian cancer	0.00196	0.00278	CcSEcCtD
Methsuximide—Dermatitis—Paclitaxel—ovarian cancer	0.00196	0.00278	CcSEcCtD
Methsuximide—Nervousness—Doxorubicin—ovarian cancer	0.00195	0.00278	CcSEcCtD
Methsuximide—Leukopenia—Epirubicin—ovarian cancer	0.00195	0.00277	CcSEcCtD
Methsuximide—Headache—Paclitaxel—ovarian cancer	0.00195	0.00276	CcSEcCtD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—APC—ovarian cancer	0.00193	0.0143	CbGpPWpGaD
Methsuximide—CYP2C19—Tamoxifen metabolism—CYP1B1—ovarian cancer	0.0019	0.0141	CbGpPWpGaD
Methsuximide—Vision blurred—Doxorubicin—ovarian cancer	0.0019	0.00269	CcSEcCtD
Methsuximide—Nausea—Paclitaxel—ovarian cancer	0.00184	0.00262	CcSEcCtD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—TLR4—ovarian cancer	0.00181	0.0135	CbGpPWpGaD
Methsuximide—Leukopenia—Doxorubicin—ovarian cancer	0.0018	0.00256	CcSEcCtD
Methsuximide—Diarrhoea—Docetaxel—ovarian cancer	0.0018	0.00256	CcSEcCtD
Methsuximide—Confusional state—Epirubicin—ovarian cancer	0.00179	0.00254	CcSEcCtD
Methsuximide—CACNA1I—Developmental Biology—HNF1B—ovarian cancer	0.00179	0.0133	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—NR5A1—ovarian cancer	0.00179	0.0133	CbGpPWpGaD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—CDH1—ovarian cancer	0.00177	0.0132	CbGpPWpGaD
Methsuximide—CACNA1I—NCAM signaling for neurite out-growth—NRAS—ovarian cancer	0.00176	0.0131	CbGpPWpGaD
Methsuximide—Dizziness—Docetaxel—ovarian cancer	0.00174	0.00247	CcSEcCtD
Methsuximide—CACNA1H—Developmental Biology—NR5A1—ovarian cancer	0.00173	0.0129	CbGpPWpGaD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—ovarian cancer	0.00171	0.0127	CbGpPWpGaD
Methsuximide—Anorexia—Epirubicin—ovarian cancer	0.00169	0.0024	CcSEcCtD
Methsuximide—CACNA1I—NCAM signaling for neurite out-growth—MAPK3—ovarian cancer	0.00169	0.0125	CbGpPWpGaD
Methsuximide—Vomiting—Docetaxel—ovarian cancer	0.00167	0.00238	CcSEcCtD
Methsuximide—Rash—Docetaxel—ovarian cancer	0.00166	0.00236	CcSEcCtD
Methsuximide—Dermatitis—Docetaxel—ovarian cancer	0.00166	0.00236	CcSEcCtD
Methsuximide—Confusional state—Doxorubicin—ovarian cancer	0.00166	0.00235	CcSEcCtD
Methsuximide—Headache—Docetaxel—ovarian cancer	0.00165	0.00234	CcSEcCtD
Methsuximide—Insomnia—Epirubicin—ovarian cancer	0.00161	0.00228	CcSEcCtD
Methsuximide—CACNA1I—NCAM signaling for neurite out-growth—MAPK1—ovarian cancer	0.0016	0.0119	CbGpPWpGaD
Methsuximide—Somnolence—Epirubicin—ovarian cancer	0.00158	0.00224	CcSEcCtD
Methsuximide—Anorexia—Doxorubicin—ovarian cancer	0.00157	0.00222	CcSEcCtD
Methsuximide—Nausea—Docetaxel—ovarian cancer	0.00156	0.00222	CcSEcCtD
Methsuximide—Decreased appetite—Epirubicin—ovarian cancer	0.00154	0.00219	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.00153	0.00218	CcSEcCtD
Methsuximide—Constipation—Epirubicin—ovarian cancer	0.00152	0.00216	CcSEcCtD
Methsuximide—CACNA1I—NCAM signaling for neurite out-growth—KRAS—ovarian cancer	0.00151	0.0113	CbGpPWpGaD
Methsuximide—Insomnia—Doxorubicin—ovarian cancer	0.00149	0.00211	CcSEcCtD
Methsuximide—CYP2C19—Melatonin metabolism and effects—CYP1B1—ovarian cancer	0.00147	0.0109	CbGpPWpGaD
Methsuximide—Feeling abnormal—Epirubicin—ovarian cancer	0.00146	0.00208	CcSEcCtD
Methsuximide—Somnolence—Doxorubicin—ovarian cancer	0.00146	0.00207	CcSEcCtD
Methsuximide—Clobazam—ABCB1—ovarian cancer	0.00146	0.138	CrCbGaD
Methsuximide—Gastrointestinal pain—Epirubicin—ovarian cancer	0.00145	0.00206	CcSEcCtD
Methsuximide—Decreased appetite—Doxorubicin—ovarian cancer	0.00143	0.00203	CcSEcCtD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—CXCL8—ovarian cancer	0.00142	0.0106	CbGpPWpGaD
Methsuximide—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.00142	0.00201	CcSEcCtD
Methsuximide—Urticaria—Epirubicin—ovarian cancer	0.00141	0.002	CcSEcCtD
Methsuximide—Constipation—Doxorubicin—ovarian cancer	0.0014	0.002	CcSEcCtD
Methsuximide—Abdominal pain—Epirubicin—ovarian cancer	0.0014	0.00199	CcSEcCtD
Methsuximide—Feeling abnormal—Doxorubicin—ovarian cancer	0.00135	0.00192	CcSEcCtD
Methsuximide—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.00134	0.00191	CcSEcCtD
Methsuximide—Phenytoin—ABCB1—ovarian cancer	0.00133	0.126	CrCbGaD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—CCND1—ovarian cancer	0.00132	0.00984	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—HNF1B—ovarian cancer	0.00132	0.0098	CbGpPWpGaD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—CTNNB1—ovarian cancer	0.00131	0.00974	CbGpPWpGaD
Methsuximide—Urticaria—Doxorubicin—ovarian cancer	0.0013	0.00185	CcSEcCtD
Methsuximide—Abdominal pain—Doxorubicin—ovarian cancer	0.0013	0.00184	CcSEcCtD
Methsuximide—CACNA1G—NCAM signaling for neurite out-growth—NRAS—ovarian cancer	0.0013	0.00965	CbGpPWpGaD
Methsuximide—CACNA1I—NCAM signaling for neurite out-growth—HRAS—ovarian cancer	0.00129	0.00957	CbGpPWpGaD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—ovarian cancer	0.00128	0.00955	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—HNF1B—ovarian cancer	0.00128	0.0095	CbGpPWpGaD
Methsuximide—Phenobarbital—ABCB1—ovarian cancer	0.00127	0.121	CrCbGaD
Methsuximide—CACNA1H—NCAM signaling for neurite out-growth—NRAS—ovarian cancer	0.00126	0.00934	CbGpPWpGaD
Methsuximide—CACNA1G—NCAM signaling for neurite out-growth—MAPK3—ovarian cancer	0.00124	0.00924	CbGpPWpGaD
Methsuximide—CACNA1I—NCAM signaling for neurite out-growth—IL6—ovarian cancer	0.00123	0.00916	CbGpPWpGaD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—CXCL8—ovarian cancer	0.00123	0.00915	CbGpPWpGaD
Methsuximide—Diarrhoea—Epirubicin—ovarian cancer	0.00121	0.00173	CcSEcCtD
Methsuximide—CACNA1H—NCAM signaling for neurite out-growth—MAPK3—ovarian cancer	0.0012	0.00895	CbGpPWpGaD
Methsuximide—CACNA1G—NCAM signaling for neurite out-growth—MAPK1—ovarian cancer	0.00118	0.00879	CbGpPWpGaD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—CASP3—ovarian cancer	0.00118	0.00875	CbGpPWpGaD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—IL2—ovarian cancer	0.00118	0.00874	CbGpPWpGaD
Methsuximide—Dizziness—Epirubicin—ovarian cancer	0.00117	0.00167	CcSEcCtD
Methsuximide—CACNA1H—NCAM signaling for neurite out-growth—MAPK1—ovarian cancer	0.00114	0.00852	CbGpPWpGaD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—CTNNB1—ovarian cancer	0.00113	0.00844	CbGpPWpGaD
Methsuximide—Vomiting—Epirubicin—ovarian cancer	0.00113	0.0016	CcSEcCtD
Methsuximide—Diarrhoea—Doxorubicin—ovarian cancer	0.00112	0.0016	CcSEcCtD
Methsuximide—Rash—Epirubicin—ovarian cancer	0.00112	0.00159	CcSEcCtD
Methsuximide—Dermatitis—Epirubicin—ovarian cancer	0.00112	0.00159	CcSEcCtD
Methsuximide—CYP2C19—Constitutive Androstane Receptor Pathway—ABCB1—ovarian cancer	0.00112	0.00831	CbGpPWpGaD
Methsuximide—CACNA1G—NCAM signaling for neurite out-growth—KRAS—ovarian cancer	0.00112	0.0083	CbGpPWpGaD
Methsuximide—Headache—Epirubicin—ovarian cancer	0.00111	0.00158	CcSEcCtD
Methsuximide—Dizziness—Doxorubicin—ovarian cancer	0.00109	0.00154	CcSEcCtD
Methsuximide—CACNA1H—NCAM signaling for neurite out-growth—KRAS—ovarian cancer	0.00108	0.00804	CbGpPWpGaD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—ovarian cancer	0.00106	0.00789	CbGpPWpGaD
Methsuximide—Nausea—Epirubicin—ovarian cancer	0.00105	0.0015	CcSEcCtD
Methsuximide—Vomiting—Doxorubicin—ovarian cancer	0.00104	0.00148	CcSEcCtD
Methsuximide—Rash—Doxorubicin—ovarian cancer	0.00104	0.00147	CcSEcCtD
Methsuximide—Dermatitis—Doxorubicin—ovarian cancer	0.00103	0.00147	CcSEcCtD
Methsuximide—Headache—Doxorubicin—ovarian cancer	0.00103	0.00146	CcSEcCtD
Methsuximide—Nausea—Doxorubicin—ovarian cancer	0.000976	0.00139	CcSEcCtD
Methsuximide—CYP2C19—Arachidonic acid metabolism—CYP1B1—ovarian cancer	0.000949	0.00706	CbGpPWpGaD
Methsuximide—CACNA1G—NCAM signaling for neurite out-growth—HRAS—ovarian cancer	0.000949	0.00706	CbGpPWpGaD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—MAPK3—ovarian cancer	0.000945	0.00703	CbGpPWpGaD
Methsuximide—CACNA1H—NCAM signaling for neurite out-growth—HRAS—ovarian cancer	0.000919	0.00684	CbGpPWpGaD
Methsuximide—CACNA1G—NCAM signaling for neurite out-growth—IL6—ovarian cancer	0.000908	0.00676	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—MET—ovarian cancer	0.000907	0.00675	CbGpPWpGaD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—MAPK1—ovarian cancer	0.000899	0.00669	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—IL6ST—ovarian cancer	0.000889	0.00661	CbGpPWpGaD
Methsuximide—CACNA1H—NCAM signaling for neurite out-growth—IL6—ovarian cancer	0.00088	0.00654	CbGpPWpGaD
Methsuximide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	0.00082	0.0061	CbGpPWpGaD
Methsuximide—CYP2C19—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	0.00081	0.00602	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—MMP2—ovarian cancer	0.000757	0.00563	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—MET—ovarian cancer	0.000669	0.00498	CbGpPWpGaD
Methsuximide—CYP2C19—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	0.000665	0.00495	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—ERBB2—ovarian cancer	0.000663	0.00493	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—IL6ST—ovarian cancer	0.000655	0.00488	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—MET—ovarian cancer	0.000648	0.00482	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—MET—ovarian cancer	0.000648	0.00482	CbGpPWpGaD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—AKT1—ovarian cancer	0.000637	0.00474	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—IL6ST—ovarian cancer	0.000635	0.00472	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—IL6ST—ovarian cancer	0.000634	0.00472	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—MMP9—ovarian cancer	0.000569	0.00423	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—MMP2—ovarian cancer	0.000558	0.00415	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—MMP2—ovarian cancer	0.00054	0.00402	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—MMP2—ovarian cancer	0.00054	0.00402	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—VEGFA—ovarian cancer	0.000511	0.0038	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—NRAS—ovarian cancer	0.000505	0.00375	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—ERBB2—ovarian cancer	0.000489	0.00364	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—MAPK3—ovarian cancer	0.000483	0.00359	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—MET—ovarian cancer	0.000477	0.00355	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—ERBB2—ovarian cancer	0.000474	0.00352	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—ERBB2—ovarian cancer	0.000473	0.00352	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—IL6ST—ovarian cancer	0.000468	0.00348	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—MET—ovarian cancer	0.000462	0.00344	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—MAPK1—ovarian cancer	0.00046	0.00342	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—EGFR—ovarian cancer	0.00046	0.00342	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—IL6ST—ovarian cancer	0.000453	0.00337	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—KRAS—ovarian cancer	0.000434	0.00323	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—MMP9—ovarian cancer	0.000419	0.00312	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—CTNNB1—ovarian cancer	0.000414	0.00308	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—MMP9—ovarian cancer	0.000406	0.00302	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—MMP9—ovarian cancer	0.000406	0.00302	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—MMP2—ovarian cancer	0.000398	0.00296	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—MMP2—ovarian cancer	0.000386	0.00287	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—VEGFA—ovarian cancer	0.000377	0.0028	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—NRAS—ovarian cancer	0.000372	0.00277	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—HRAS—ovarian cancer	0.000369	0.00275	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—VEGFA—ovarian cancer	0.000365	0.00271	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—VEGFA—ovarian cancer	0.000365	0.00271	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—STAT3—ovarian cancer	0.000361	0.00269	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—NRAS—ovarian cancer	0.00036	0.00268	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—NRAS—ovarian cancer	0.00036	0.00268	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—MAPK3—ovarian cancer	0.000356	0.00265	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—IL6—ovarian cancer	0.000353	0.00263	CbGpPWpGaD
Methsuximide—CYP2C19—Biological oxidations—CYP1B1—ovarian cancer	0.000353	0.00263	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—ERBB2—ovarian cancer	0.000349	0.0026	CbGpPWpGaD
Methsuximide—CYP2C19—Metapathway biotransformation—CYP1B1—ovarian cancer	0.000348	0.00259	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—MAPK3—ovarian cancer	0.000345	0.00257	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—MAPK3—ovarian cancer	0.000345	0.00257	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—MAPK1—ovarian cancer	0.000339	0.00252	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—EGFR—ovarian cancer	0.000339	0.00252	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—ERBB2—ovarian cancer	0.000338	0.00251	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—MAPK1—ovarian cancer	0.000328	0.00244	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—EGFR—ovarian cancer	0.000328	0.00244	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—MAPK1—ovarian cancer	0.000328	0.00244	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—EGFR—ovarian cancer	0.000328	0.00244	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—KRAS—ovarian cancer	0.00032	0.00238	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—KRAS—ovarian cancer	0.00031	0.00231	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—KRAS—ovarian cancer	0.00031	0.00231	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—CTNNB1—ovarian cancer	0.000305	0.00227	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—MMP9—ovarian cancer	0.000299	0.00223	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—CTNNB1—ovarian cancer	0.000296	0.0022	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—MMP9—ovarian cancer	0.00029	0.00216	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	0.000272	0.00203	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—HRAS—ovarian cancer	0.000272	0.00202	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—VEGFA—ovarian cancer	0.000269	0.002	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—STAT3—ovarian cancer	0.000266	0.00198	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—NRAS—ovarian cancer	0.000265	0.00197	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—HRAS—ovarian cancer	0.000264	0.00196	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—HRAS—ovarian cancer	0.000263	0.00196	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—IL6—ovarian cancer	0.00026	0.00194	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—VEGFA—ovarian cancer	0.00026	0.00194	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—STAT3—ovarian cancer	0.000258	0.00192	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—NRAS—ovarian cancer	0.000257	0.00191	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—MAPK3—ovarian cancer	0.000254	0.00189	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—IL6—ovarian cancer	0.000252	0.00188	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—IL6—ovarian cancer	0.000252	0.00188	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—MAPK3—ovarian cancer	0.000246	0.00183	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—MAPK1—ovarian cancer	0.000242	0.0018	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—EGFR—ovarian cancer	0.000242	0.0018	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—MAPK1—ovarian cancer	0.000234	0.00174	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—EGFR—ovarian cancer	0.000234	0.00174	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—AKT1—ovarian cancer	0.000233	0.00173	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—KRAS—ovarian cancer	0.000228	0.0017	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—KRAS—ovarian cancer	0.000221	0.00165	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—NME2—ovarian cancer	0.000215	0.0016	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—HRAS—ovarian cancer	0.000194	0.00144	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—HRAS—ovarian cancer	0.000188	0.0014	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—IL6—ovarian cancer	0.000186	0.00138	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	0.000183	0.00136	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—IL6—ovarian cancer	0.00018	0.00134	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—AKT1—ovarian cancer	0.000171	0.00128	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—AKT1—ovarian cancer	0.000166	0.00124	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	0.000149	0.00111	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—CYTB—ovarian cancer	0.000139	0.00103	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	0.000136	0.00101	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PPP1CC—ovarian cancer	0.000121	0.000902	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—BRIP1—ovarian cancer	0.000121	0.000902	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	8.84e-05	0.000658	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—YAP1—ovarian cancer	8.14e-05	0.000605	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	8.05e-05	0.000599	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	7.08e-05	0.000527	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—FASN—ovarian cancer	6.63e-05	0.000493	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—SLC5A5—ovarian cancer	6.52e-05	0.000485	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—SLC2A1—ovarian cancer	6.3e-05	0.000469	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	6.17e-05	0.000459	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—CYP1B1—ovarian cancer	6.04e-05	0.000449	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PPP2R1A—ovarian cancer	5.36e-05	0.000399	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	5.33e-05	0.000397	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—ABCB1—ovarian cancer	4.97e-05	0.00037	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—TYMS—ovarian cancer	4.89e-05	0.000363	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—CAV1—ovarian cancer	3.94e-05	0.000293	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	3.76e-05	0.00028	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PIK3CG—ovarian cancer	3.59e-05	0.000267	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PIK3CD—ovarian cancer	3.15e-05	0.000234	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PIK3CB—ovarian cancer	2.75e-05	0.000204	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PTEN—ovarian cancer	2.37e-05	0.000177	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PIK3CA—ovarian cancer	1.68e-05	0.000125	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—AKT1—ovarian cancer	1.37e-05	0.000102	CbGpPWpGaD
